FOXO1在口腔鳞状细胞癌中的研究进展

doi:10.3760/cma.j.cn371439-20220414-00121

国际肿瘤学杂志 ›› 2022, Vol. 49 ›› Issue (10): 612-614.doi: 10.3760/cma.j.cn371439-20220414-00121

FOXO1在口腔鳞状细胞癌中的研究进展

杨帆¹, 管晓燕^1,², 刘建国², 肖琳琳^1,², 岳超弈³, 龙茜^1,², 廖成成^1,²()

¹遵义医科大学附属口腔医院正畸科二组，遵义 563000
²贵州省普通高等学校口腔疾病研究特色重点实验室，遵义 563000
³遵义医科大学医学与科技学院，遵义 563000

收稿日期:2022-04-14 修回日期:2022-05-16 出版日期:2022-10-08 发布日期:2022-12-01
通讯作者: 廖成成 E-mail:lcc_950330@163.com
基金资助:
国家重点研发计划(2016YFC1102800);贵州省医用生物材料研发人才基地项目(QianRenLingFa [2018] 3)

Research progress of FOXO1 in oral squamous cell carcinoma

Yang Fan¹, Guan Xiaoyan^1,², Liu Jianguo², Xiao Linlin^1,², Yue Chaoyi³, Long Qian^1,², Liao Chengcheng^1,²()

¹Department of Orthodontics Ⅱ， Affiliated Stomatological Hospital of Zunyi Medical University， Zunyi 563000， China
²Guizhou Provincial Key Laboratory of Oral Disease Research in Colleges and Universities， Zunyi 563000， China
³School of Medicine and Technology， Zunyi Medical University， Zunyi 563000， China

Received:2022-04-14 Revised:2022-05-16 Online:2022-10-08 Published:2022-12-01
Contact: Liao Chengcheng E-mail:lcc_950330@163.com
Supported by:
National Key Research and Development Program(2016YFC1102800);Guizhou Province Medical Biomaterials Research and Development Talent Base Project(QianRenLingFa [2018] 3)

摘要/Abstract

摘要：

叉头框蛋白O1（FOXO1）是一种肿瘤抑制因子。在口腔鳞状细胞癌中，研究证实FOXO1能够抑制肿瘤细胞氧化应激、干细胞性和上皮间质转化，并促进肿瘤细胞自噬和凋亡。FOXO1可作为治疗口腔鳞状细胞癌的潜在靶点。

关键词: 叉头框蛋白O1, 口腔肿瘤

Abstract:

Forkhead box protein O1（FOXO1） has been extensively studied as a tumor suppressor. In oral squamous cell carcinoma， studies have demonstrated that FOXO1 can inhibit tumor cell oxidative stress， stemness and epithelial-mesenchymal transition， and promote tumor cell autophagy and apoptosis. FOXO1 may serve as a potential target for the treatment of oral squamous cell carcinoma.

Key words: Forkhead box protein O 1, Oral neoplasms

杨帆, 管晓燕, 刘建国, 肖琳琳, 岳超弈, 龙茜, 廖成成. FOXO1在口腔鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 612-614.

Yang Fan, Guan Xiaoyan, Liu Jianguo, Xiao Linlin, Yue Chaoyi, Long Qian, Liao Chengcheng. Research progress of FOXO1 in oral squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(10): 612-614.

参考文献 27

[1]	石雨, 陈曦, 许梦琪, 等. 沉默PSIP1基因对口腔鳞状细胞癌细胞迁移及侵袭的影响[J]. 国际肿瘤学杂志, 2022, 49(3): 129-133. DOI: 10.3760/cma.j.cn371439-20210917-00022. doi: 10.3760/cma.j.cn371439-20210917-00022
[2]	Saikishore R, Velmurugan P, Ranjithkumar D, et al. The circular RNA-miRNA axis: a special RNA signature regulatory transcriptome as a potential biomarker for OSCC[J]. Mol Ther Nucleic Acids, 2020, 22: 352-361. DOI: 10.1016/j.omtn.2020.09.001. doi: 10.1016/j.omtn.2020.09.001
[3]	Farhan M, Wang H, Gaur U, et al. FOXO signaling pathways as therapeutic targets in cancer[J]. Int J Biol Sci, 2017, 13(7): 815-827. DOI: 10.7150/ijbs.20052. doi: 10.7150/ijbs.20052 pmid: 28808415
[4]	Soh R, Hardy A, Zur Nieden NI. The FOXO signaling axis displays conjoined functions in redox homeostasis and stemness[J]. Free Radic Biol Med, 2021, 169: 224-237. DOI: 10.1016/j.freeradbiomed.2021.04.022. doi: 10.1016/j.freeradbiomed.2021.04.022
[5]	Calissi G, Lam EW, Link W. Therapeutic strategies targeting FOXO transcription factors[J]. Nat Rev Drug Discov, 2021, 20(1): 21-38. DOI: 10.1038/s41573-020-0088-2. doi: 10.1038/s41573-020-0088-2 pmid: 33173189
[6]	Liao C, Wang Q, An J, et al. Partial EMT in squamous cell carcinoma: a snapshot[J]. Int J Biol Sci, 2021, 17(12): 3036-3047. DOI: 10.7150/ijbs.61566. doi: 10.7150/ijbs.61566 pmid: 34421348
[7]	Zheng M, Cao MX, Luo XJ, et al. EZH2 promotes invasion and tumour glycolysis by regulating STAT3 and FoxO1 signalling in human OSCC cells[J]. J Cell Mol Med, 2019, 23(10): 6942-6954. DOI: 10.1111/jcmm.14579. doi: 10.1111/jcmm.14579 pmid: 31368152
[8]	Yang X, Sun T, Zhao Y, et al. 4sc-202 and Ink-128 cooperate to reverse the epithelial to mesenchymal transition in OSCC[J]. Oral Dis, 2021. DOI: 10.1111/odi.13860. doi: 10.1111/odi.13860
[9]	廖成成, 安家兴, 谭张雪, 等. 口腔鳞状细胞癌干细胞的治疗靶点及应用前景[J]. 中国组织工程研究, 2021, 25(7): 1096-1103. DOI: 10.3969/j.issn.2095-4344.2126. doi: 10.3969/j.issn.2095-4344.2126
[10]	Liu W, Chen G. Regulation of energy metabolism in human pluripotent stem cells[J]. Cell Mol Life Sci, 2021, 78(24): 8097-8108. DOI: 10.1007/s00018-021-04016-0. doi: 10.1007/s00018-021-04016-0 pmid: 34773132
[11]	Saha T, Lukong KE. Breast cancer stem-like cells in drug resistance: a review of mechanisms and novel therapeutic strategies to overcome drug resistance[J]. Front Oncol, 2022, 12: 856974. DOI: 10.3389/fonc.2022.856974. doi: 10.3389/fonc.2022.856974
[12]	Dorna D, Paluszczak J. The emerging significance of histone lysine demethylases as prognostic markers and therapeutic targets in head and neck cancers[J]. Cells, 2022, 11(6): 1023. DOI: 10.3390/cells11061023. doi: 10.3390/cells11061023
[13]	Shi C, Wang L, Sen P. The eroding chromatin landscape of aging stem cells[J]. Transl Med Aging, 2020, 4: 121-131. DOI: 10.1016/j.tma.2020.08.002. doi: 10.1016/j.tma.2020.08.002
[14]	Onorati AV, Dyczynski M, Ojha R, et al. Targeting autophagy in cancer[J]. Cancer, 2018, 124(16): 3307-3318. DOI: 10.1002/cncr.31335. doi: 10.1002/cncr.31335 pmid: 29671878
[15]	Zhou L, Guo J, Jia R. Oncogene SRSF3 suppresses autophagy via inhibiting BECN1 expression[J]. Biochem Biophys Res Commun, 2019, 509(4): 966-972. DOI: 10.1016/j.bbrc.2019.01.048. doi: 10.1016/j.bbrc.2019.01.048
[16]	Xing YQ, Li A, Yang Y, et al. The regulation of FOXO1 and its role in disease progression[J]. Life Sci, 2018, 193: 124-131. DOI: 10.1016/j.lfs.2017.11.030. doi: S0024-3205(17)30607-0 pmid: 29158051
[17]	Liang J, Yang B, Zhou X, et al. Stimuli-responsive drug delivery systems for head and neck cancer therapy[J]. Drug Deliv, 2021, 28(1): 272-284. DOI: 10.1080/10717544.2021.1876182. doi: 10.1080/10717544.2021.1876182 pmid: 33501883
[18]	Lin CC, Yang CC, Hsiao LD, et al. Carbon monoxide releasing molecule-3 enhances heme oxygenase-1 induction via ROS-dependent FoxO1 and Nrf2 in brain astrocytes[J]. Oxid Med Cell Longev, 2021, 2021: 5521196. DOI: 10.1155/2021/5521196. doi: 10.1155/2021/5521196
[19]	Remadevi V, Muraleedharan P, Sreeja S. FOXO1: a pivotal pioneer factor in oral squamous cell carcinoma[J]. Am J Cancer Res, 2021: 11(10): 4700-4710. pmid: 34765288
[20]	Zhang Y, Xiong Y, Zhou J, et al. FoxO1 expression in osteoblasts modulates bone formation through resistance to oxidative stress in mice[J]. Biochem Biophys Res Commun, 2018, 503(3): 1401-1408. DOI: 10.1016/j.bbrc.2018.07.055. doi: 10.1016/j.bbrc.2018.07.055
[21]	Sekar M, Thirumurugan K. Autophagy: a molecular switch to regulate adipogenesis and lipolysis[J]. Mol Cell Biochem, 2022, 477(3): 727-742. DOI: 10.1007/s11010-021-04324-w. doi: 10.1007/s11010-021-04324-w pmid: 35022960
[22]	Zhao C, Zhang Z, Dai X, et al. Actein antagonizes oral squamous cell carcinoma proliferation through activating FoxO1[J]. Pharmacology, 2021, 106(9-10): 551-563. DOI: 10.1159/000 515601. doi: 10.1159/000 515601
[23]	Song H, Lai L, Liu M, et al. Investigating the role and mechanism of microRNA-196a in oral squamous cell carcinoma by targeting FOXO1[J]. Exp Ther Med, 2020, 19(6): 3707-3715. DOI: 10.3892/etm.2020.8614. doi: 10.3892/etm.2020.8614 pmid: 32346435
[24]	Xu Y, Pan S, Jiang W, et al. Effects of propofol on the development of cancer in humans[J]. Cell Prolif, 2020, 53(8): e12867. DOI: 10.1111/cpr.12867. doi: 10.1111/cpr.12867
[25]	Shi F, Li T, Liu Z, et al. FOXO1: another avenue for treating digestive malignancy?[J]. Semin Cancer Biol, 2018, 50:124-131. DOI: 10.1016/j.semcancer.2017.09.009. doi: S1044-579X(17)30183-9 pmid: 28965871
[26]	Silva P, Latruffe N, Gaetano G. Wine consumption and oral cavity cancer: friend or foe, two faces of Janus[J]. Molecules, 2020, 25(11): 2569. DOI: 10.3390/molecules25112569. doi: 10.3390/molecules25112569
[27]	Körholz K, Ridinger J, Krunic D, et al. Broad-spectrum HDAC inhibitors promote autophagy through FOXO transcription factors in neuroblastoma[J]. Cells, 2021, 10(5): 1001. DOI: 10.3390/cells10051001. doi: 10.3390/cells10051001

FOXO1在口腔鳞状细胞癌中的研究进展

Research progress of FOXO1 in oral squamous cell carcinoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 6

编辑推荐

Metrics

本文评价

[1]	石雨, 陈曦, 许梦琪, 张滢滢, 冀洪海, 蒋英英. 沉默PSIP1基因对口腔鳞状细胞癌细胞迁移及侵袭的影响[J]. 国际肿瘤学杂志, 2022, 49(3): 129-133.
[2]	劳峥, 涂文勇, 徐璇丽, 张霖, 邵滋旸, 石慧烽. 尼妥珠单抗联合根治性放疗治疗局部晚期不可手术的口腔颌面部鳞状细胞癌[J]. 国际肿瘤学杂志, 2022, 49(11): 665-670.
[3]	周昌群, 管晓燕, 刘建国, 岳超弈, 廖成成. 口腔黏膜下纤维化恶变的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 608-611.
[4]	郝瑞,梁艳. 口腔舌鳞状细胞癌患者血清多配体聚糖-1表达水平及临床意义[J]. 国际肿瘤学杂志, 2018, 45(4): 193-196.
[5]	林建英, 杨熙鸿, 郭海鹏, 徐漫彬, 许少伟, 彭汉伟. 近红外线吲哚氰绿荧光显像法在cN₀口腔癌前哨淋巴结活检中的应用[J]. 国际肿瘤学杂志, 2016, 43(2): 86-.
[6]	马萍, 金武龙. 纳米靶向给药系统与口腔癌治疗[J]. 国际肿瘤学杂志, 2014, 41(10): 753-756.